ArticleFrontiers in immunology2025
Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is currently no established standard treatment for patients with metastatic hepatocellular carcinoma after resistance to tyrosine kinase inhibitors. Given that radiotherapy can reprogram the tumor microenvironment and convert "cold" tumors into "hot" tumors, combining radiotherapy with immunotherapy shows significant potential. In this case, we present a male patient with HBV-related metastatic hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis. The patient achieved abscopal effect with a progression-free survival of 10 months and an overall survival of 21 months with the combination of anti-PD-1 therapy and stereotactic body radiotherapy (SBRT) as third-line treatment. This combination therapy demonstrates relative efficacy and favorability in treating HBV-related advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.